Ambit Biosciences Announces Presentations Of Data From Clinical Investigations Of Quizartinib At The Annual Meeting Of The American Society of Clinical Oncology

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced two abstracts to be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3, 2014, at McCormick Place in Chicago.

"I am pleased that once again we will have presentations at ASCO highlighting our Phase 2 studies with quizartinib," said Athena Countouriotis, chief medical officer at Ambit. "We look forward to further discussing the abstracts once publically released in May."

Information about the abstracts, including presentation time and location, is listed below:

Abstract No.: 7100
Title: Final Results of a Randomized Phase 2 Study Showing the Clinical Benefit of Quizartinib (AC220) in Patients with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia
Presenter: Gary J. Schiller, MD
Poster Board: 385
Session: Leukemia, Myelodysplasia, and Transplantation
On Display: Monday, June 2, 1:15pm to 5:00pm (CDT) in S Hall A2

Abstract No.: 7093
Title: The Benefit of Treatment with Quizartinib and Subsequent Bridging to HSCT for FLT3-ITD(+) Patients with AML
Presenter: Mark J. Levis, MD, PhD
Poster Board: 378
Session: Leukemia, Myelodysplasia, and Transplantation
On Display: Monday, June 2, 1:15pm to 5:00pm (CDT) in S Hall A2

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently in a registrational Phase 3 clinical trial, referred to as QUANTUM-R, in patients with relapsed/refractory acute myeloid leukemia (AML). Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward Looking Statements
Statements in this report that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the future development and therapeutic potential of quizartinib and our other drug candidates. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those projected in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. For a discussion of these and other risks please refer to Ambit's Annual Report on Form 10-K for the year ended December 31, 2013 and Ambit's other periodic filings with the SEC. All forward-looking statements contained in this report speak only as of the date on which they were made. Ambit does not undertake any obligation to update forward-looking statements.

SOURCE Ambit Biosciences